FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/06/2026
Back to search
Official data from USPTO
AUTOLUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
08/06/2026
Trademark type
Combined
Nice classes
5, 40, 42, 44
Filing date
01/27/2025
Registration date
01/13/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/13/2026
Last transaction
08/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
HARMON, RAYMOND E
Law office
L30
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "AUTOLUS" where a design of a shaded circle with a smaller circle carving out a space in its upper-left takes the place of the letter "O".
Holders and representatives
Holders
Autolus Limited
Representatives
Rebecca Liebowitz Venable LLP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical and veterinary preparations for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposesin particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapyin particular T cell therapy; vaccines
Class 40
Custom manufacture of therapeutic drugsnamely cell therapiespreparations to treat autoimmune diseasescancer therapies and cancer vaccines
Class 42
Scientific and technological services and research and design relating theretomedical researchscientific researchanalysis and testing in the field of human and animal cellgene and cancer therapiespharmaceutical product developmentresearch and development of new products; industrial analysis and research services in the field of cellgene and cancer therapies; medical and veterinary research servicesin particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccinesin particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services
Class 44
Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical servicesmanipulation of human and animal cells for therapeutic purposes; medical servicesreinsertion of cells into human and animal patients; medical and veterinary servicesproviding advice and consultancy in the field of medical and veterinary therapies; medical and veterinary servicesproviding advice and consultancy in the field of autoimmune diseasescancer therapies and cancer vaccines
Publications
History of USPTO decisions and trademark events.
22 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/19/2026
FIMP
FINAL DISPOSITION PROCESSED
07/19/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/13/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/13/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
01/13/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/25/2025
PUBO
PUBLISHED FOR OPPOSITION
11/25/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/19/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/27/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/27/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/27/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/27/2025
RFNT
REFUSAL PROCESSED BY IB
07/12/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/21/2025
RFRR
REFUSAL PROCESSED BY MPU
06/21/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/18/2025
CNRT
NON-FINAL ACTION WRITTEN
04/17/2025
DOCK
ASSIGNED TO EXAMINER
04/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
04/04/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/03/2025
Continuous trademark protection
Get notified about every new filing that threatens AUTOLUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.